{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T15:30:11Z","timestamp":1759073411948,"version":"3.41.2"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2014,12,1]],"date-time":"2014-12-01T00:00:00Z","timestamp":1417392000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100002293","name":"European Regional Development Fund","doi-asserted-by":"publisher","award":["POIG.01.01.02-12-004\/09-00"],"award-info":[{"award-number":["POIG.01.01.02-12-004\/09-00"]}],"id":[{"id":"10.13039\/100002293","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Reports"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1016\/j.pharep.2014.06.009","type":"journal-article","created":{"date-parts":[[2014,6,21]],"date-time":"2014-06-21T17:00:39Z","timestamp":1403370039000},"page":"984-990","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["The effect of risperidone on the mirtazapine-induced changes in extracellular monoamines in the rat frontal cortex"],"prefix":"10.1007","volume":"66","author":[{"given":"Katarzyna","family":"Kami\u0144ska","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krystyna","family":"Go\u0142embiowska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zofia","family":"Rog\u00f3\u017c","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"issue":"3","key":"10.1016\/j.pharep.2014.06.009_bib0005","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1002\/phar.1204","article-title":"Augmentation with atypical antipsychotics for depression. A review of evidence-based support from the medical literature","volume":"33","author":"Wright","year":"2013","journal-title":"Pharmacotherapy"},{"issue":"2","key":"10.1016\/j.pharep.2014.06.009_bib0010","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/S0193-953X(05)70293-8","article-title":"Treatment algorithms in treatment-resistant depression","volume":"19","author":"Amsterdam","year":"1996","journal-title":"Psychiatry Clin North Am"},{"issue":"Suppl. 4","key":"10.1016\/j.pharep.2014.06.009_bib0015","first-page":"57","article-title":"Treatment options for refractory depression","volume":"60","author":"Shelton","year":"1999","journal-title":"J Clin Psychiatry"},{"issue":"4","key":"10.1016\/j.pharep.2014.06.009_bib0020","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1111\/j.1600-0447.2007.01130.x","article-title":"Augmentation of antidepressants with atypical antipsychotics for treatment-resistant major depressive disorder","volume":"117","author":"Shelton","year":"2008","journal-title":"Acta Psychiatry Scand"},{"issue":"1","key":"10.1016\/j.pharep.2014.06.009_bib0025","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/S1734-1140(13)70961-7","article-title":"Influence of aripiprazole and olanzapine on behavioral dysfunctions of adolescent rats exposed to stress in perinatal period","volume":"65","author":"Ratajczak","year":"2013","journal-title":"Pharmacol Rep"},{"issue":"1","key":"10.1016\/j.pharep.2014.06.009_bib0030","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S1734-1140(13)70960-5","article-title":"New 8-aminoakryl derivatives of purine-2,6-dione with arylalkyl, aryl or propynyl substituents in position 7, their 5-HT1A, 5-HT2A, and 5-HT7 receptor affinity and pharmacological evaluation","volume":"65","author":"Ch\u0142o\u0144-Rzepa","year":"2013","journal-title":"Pharmacol Rep"},{"issue":"8","key":"10.1016\/j.pharep.2014.06.009_bib0035","doi-asserted-by":"crossref","first-page":"733","DOI":"10.4088\/JCP.v63n0812","article-title":"An open pilot study combining risperidone and selective serotonin reuptake inhibitor as initial antidepressant therapy","volume":"63","author":"Hirose","year":"2002","journal-title":"J Clin Psychiatry"},{"issue":"3","key":"10.1016\/j.pharep.2014.06.009_bib0040","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.jpsychires.2008.05.003","article-title":"A randomized, placebo-controlled trial of risperidone augmentation for patients with difficult-to-treat unipolar, non-psychotic major depression","volume":"43","author":"Keitner","year":"2009","journal-title":"J Psychiatry Res"},{"issue":"1","key":"10.1016\/j.pharep.2014.06.009_bib0045","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1097\/00004714-199802000-00018","article-title":"Additing risperidone to selective serotonin reuptake inhibitor improves chronic depression","volume":"18","author":"O\u2019Connor","year":"1998","journal-title":"J Clin Psychopharmacol"},{"issue":"4","key":"10.1016\/j.pharep.2014.06.009_bib0050","doi-asserted-by":"crossref","first-page":"256","DOI":"10.4088\/JCP.v60n0410","article-title":"Risperidone augmentation of selective serotonin reuptake inhibitors in major depression","volume":"60","author":"Ostroff","year":"1999","journal-title":"J Clin Psychiatry"},{"issue":"11","key":"10.1016\/j.pharep.2014.06.009_bib0055","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1038\/sj.npp.1301113","article-title":"Effects of risperidone augmentation in patients with treatment-resistant depression: results of open-label treatment followed by double-blind continuation","volume":"31","author":"Rapaport","year":"2006","journal-title":"Neuropsychopharmacology"},{"issue":"1\u20133","key":"10.1016\/j.pharep.2014.06.009_bib0060","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S0014-2999(02)02957-6","article-title":"Comparative behavioral effects of typical and atypical antipsychotic drugs in rhesus monkey","volume":"462","author":"Kumar","year":"2003","journal-title":"Eur J Pharmacol"},{"issue":"1","key":"10.1016\/j.pharep.2014.06.009_bib0065","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0024-3205(00)00911-5","article-title":"Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds","volume":"68","author":"Richelson","year":"2000","journal-title":"Life Sci"},{"issue":"1\u20132","key":"10.1016\/j.pharep.2014.06.009_bib0070","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/BF02245606","article-title":"Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding","volume":"124","author":"Schotte","year":"1996","journal-title":"Psychopharmacology (Berl)"},{"issue":"5","key":"10.1016\/j.pharep.2014.06.009_bib0075","doi-asserted-by":"crossref","first-page":"427","DOI":"10.2165\/00023210-200923050-00006","article-title":"Mirtazapine: a review of its use in major depression and other psychiatric disorders","volume":"23","author":"Croom","year":"2009","journal-title":"CNS Drugs"},{"issue":"6","key":"10.1016\/j.pharep.2014.06.009_bib0080","first-page":"1191","article-title":"Effects of co-treatment with mirtazapine and low doses of risperidone on the immobility time in the forced swimming test in mice","volume":"62","author":"Rog\u00f3\u017c","year":"2010","journal-title":"Pharmacol Rep"},{"issue":"6","key":"10.1016\/j.pharep.2014.06.009_bib0085","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1016\/S1734-1140(11)70717-4","article-title":"Enhancement of the anti-immobility action of antidepressants by risperidone in the forced swimming test in mice","volume":"63","author":"Rog\u00f3\u017c","year":"2011","journal-title":"Pharmacol Rep"},{"issue":"6","key":"10.1016\/j.pharep.2014.06.009_bib0090","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1016\/S1734-1140(12)70936-2","article-title":"Effect of co-treatment with fluoxetine or mirtazapine and risperidone on the active behaviors and plasma corticosterone concentration in rats subjected to the forced swim test","volume":"64","author":"Rog\u00f3\u017c","year":"2012","journal-title":"Pharmacol Rep"},{"issue":"3","key":"10.1016\/j.pharep.2014.06.009_bib0095","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1001\/archpsyc.1989.01810030049007","article-title":"Reduction of prefrontal cortex glucose metabolism common to three types of depression","volume":"46","author":"Baxter","year":"1989","journal-title":"Arch Gen Psychiatry"},{"issue":"2","key":"10.1016\/j.pharep.2014.06.009_bib0100","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/0165-0327(86)90036-4","article-title":"Frontal cortex and basal ganglia metabolic rates assessed by positron emission tomography with [18F]2-deoxyglucose in affective illness","volume":"10","author":"Buchsbaum","year":"1986","journal-title":"J Affect Disord"},{"issue":"4","key":"10.1016\/j.pharep.2014.06.009_bib0105","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1046\/j.1471-4159.2001.00148.x","article-title":"Inhibition of stress- or anxiogenic-drug-induced increases in dopamine release in the rat prefrontal cortex by long-term treatment with antidepressant drugs","volume":"76","author":"Dazzi","year":"2001","journal-title":"J Neurochem"},{"issue":"1\u20132","key":"10.1016\/j.pharep.2014.06.009_bib0110","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/BF02244785","article-title":"Increase of extracellular dopamine in the prefrontal cortex: a trait of drug with antidepressant potential?","volume":"115","author":"Tanda","year":"1994","journal-title":"Psychopharmacology (Berl)"},{"issue":"2","key":"10.1016\/j.pharep.2014.06.009_bib0115","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/BF02805978","article-title":"Chronic desipramine and fluoxetine differentially affect extracellular dopamine in the rat prefrontal cortex","volume":"127","author":"Tanda","year":"1996","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.pharep.2014.06.009_bib0120","series-title":"Psychopharmacology: the fourth generation of progress","first-page":"933","article-title":"The serotonin hypothesis of major depression","author":"Maes","year":"1995"},{"key":"10.1016\/j.pharep.2014.06.009_bib0125","series-title":"Psychopharmacology: the fourth generation of progress","first-page":"911","article-title":"Recent studies on norepinephrine systems in mood disorders","author":"Schatzberg","year":"1995"},{"key":"10.1016\/j.pharep.2014.06.009_bib0130","series-title":"Psychopharmacology: the fourth generation of progress","first-page":"921","article-title":"Dopaminergic mechanism in depression and mania","author":"Willner","year":"1995"},{"issue":"3","key":"10.1016\/j.pharep.2014.06.009_bib0135","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.brainresbull.2004.02.007","article-title":"Mirtazapine increases dopamine release in prefrontal cortex by 5-HT1A receptor activation","volume":"63","author":"Nakayama","year":"2004","journal-title":"Brain Res Bull"},{"issue":"5437","key":"10.1016\/j.pharep.2014.06.009_bib0140","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1126\/science.286.5437.105","article-title":"Enhanced cortical dopamine output and antipsychotic-like effects of raclopride by \u03b12 adrenoceptor blockade","volume":"268","author":"Hertel","year":"1999","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.pharep.2014.06.009_bib0145","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/S0893-133X(97)00002-X","article-title":"Risperidone dose-dependently increases extracellular concentrations of serotonin the rat frontal cortex: role of alpha 2-adrenoreceptors antagonism","volume":"17","author":"Hertel","year":"1997","journal-title":"Neuropsychopharmacology"},{"issue":"2","key":"10.1016\/j.pharep.2014.06.009_bib0150","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/S0022-3565(24)38019-X","article-title":"Effect of antipsychotic drugs on extracellular dopamine levels in rat medial prefrontal cortex and nucleus accumbens","volume":"288","author":"Kuroki","year":"1999","journal-title":"J Pharmacol Exp Ther"},{"issue":"2","key":"10.1016\/j.pharep.2014.06.009_bib0155","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s002130050551","article-title":"Olanzapine increases in vitro dopamine and noradrenaline release in rat prefrontal cortex, nucleus accumbens and striatum","volume":"136","author":"Li","year":"1998","journal-title":"Psychopharmacology (Berl)"},{"issue":"1","key":"10.1016\/j.pharep.2014.06.009_bib0160","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1046\/j.1471-4159.1997.69010182.x","article-title":"BIMG 80, a novel potential antipsychotics drugs: evidence for multireceptor actions and prefrontal release of dopamine in prefrontal cortex","volume":"69","author":"Volonte","year":"1997","journal-title":"J Neurochem"},{"issue":"3","key":"10.1016\/j.pharep.2014.06.009_bib0165","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/S0893-133X(00)00119-6","article-title":"Synergistic effect of olanzapine and other antipsychotic agents in combination with fluoxetine on norepinephrine and dopamine release in rat prefrontal cortex","volume":"23","author":"Zhang","year":"2000","journal-title":"Neuropsychopharmacology"},{"issue":"2","key":"10.1016\/j.pharep.2014.06.009_bib0170","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0014-2999(98)00308-2","article-title":"Effect of antipsychotic drugs on extracellular serotonin levels in rat medial prefrontal cortex and nucleus accumbens","volume":"351","author":"Ichikawa","year":"1998","journal-title":"Eur J Pharmacol"},{"issue":"5","key":"10.1016\/j.pharep.2014.06.009_bib0175","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1016\/S1734-1140(13)71472-5","article-title":"The effect of risperidone on the fluoxetine-induced changes in extracellular dopamine, serotonin and noradrenaline in the rat frontal cortex","volume":"65","author":"Kami\u0144ska","year":"2013","journal-title":"Pharmacol Rep"},{"issue":"Suppl. 10","key":"10.1016\/j.pharep.2014.06.009_bib0180","first-page":"28","article-title":"In vitro and in vivo biochemistry of olanzapine: a novel atypical antipsychotic drug","volume":"58","author":"Bymaster","year":"1997","journal-title":"J Clin Psychiatry"},{"issue":"2","key":"10.1016\/j.pharep.2014.06.009_bib0185","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/S0022-3565(25)38366-7","article-title":"Characterization of 5-HT2 receptor antagonist MDL 100907 as a putative atypical antipsychotic: behavioral, electrophysiological and neurochemical studies","volume":"266","author":"Sorensen","year":"1993","journal-title":"J Pharmacol Exp Ther"},{"issue":"3","key":"10.1016\/j.pharep.2014.06.009_bib0190","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1111\/j.1440-1819.2011.02191.x","article-title":"Mirtazapine in combination with perospirone synergistically enhances dopamine release in the rat prefrontal cortex via 5-HT1A receptor activation","volume":"65","author":"Morita","year":"2011","journal-title":"Psychiatry Clin Neurosci"},{"issue":"1\u20133","key":"10.1016\/j.pharep.2014.06.009_bib0195","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/0014-2999(96)00150-1","article-title":"Ipsapirone enhances the dopamine outflow via 5-HT1A receptors in the rat prefrontal cortex","volume":"305","author":"W\u0119dzony","year":"1996","journal-title":"Eur J Pharmacol"},{"issue":"3","key":"10.1016\/j.pharep.2014.06.009_bib0200","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1002\/(SICI)1098-2396(199611)24:3<240::AID-SYN6>3.0.CO;2-E","article-title":"Evidence that conditioned stress enhances outflow of dopamine in rat prefrontal cortex: a search for the influence of diazepam and 5-HT1A agonists","volume":"24","author":"W\u0119dzony","year":"1996","journal-title":"Synapse"},{"issue":"3","key":"10.1016\/j.pharep.2014.06.009_bib0205","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1002\/cne.1147","article-title":"Targeting of serotonin 1A receptors to dopaminergic neurons within the parabrachial subdivision of the ventral tegmental area in rat brain","volume":"433","author":"Doherty","year":"2001","journal-title":"J Comp Neurol"},{"issue":"4","key":"10.1016\/j.pharep.2014.06.009_bib0210","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/BF00165384","article-title":"The 5-HT1A receptor selective ligands, (R)-8-OH-DPAT and (S)-UH-301, differentially affect the activity of midbrain dopamine neurons","volume":"347","author":"Arborelius","year":"1993","journal-title":"Naunyn-Schmiedebergs Arch Pharmacol"},{"issue":"3","key":"10.1016\/j.pharep.2014.06.009_bib0215","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/0306-4522(85)90141-1","article-title":"Regulation of dopamine release by impulse flow and by autoreceptors as studied by in vivo voltammetry in the rat striatum","volume":"14","author":"Gonon","year":"1985","journal-title":"Neuroscience"},{"issue":"1","key":"10.1016\/j.pharep.2014.06.009_bib0220","first-page":"162","article-title":"Biochemical profile of YM992, a novel selective serotonin reuptake inhibitor with 5-HT2A receptor antagonistic activity","volume":"35","author":"Hatanake","year":"1996","journal-title":"Neuropharmacology"},{"issue":"2","key":"10.1016\/j.pharep.2014.06.009_bib0225","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/S0306-4522(97)00565-4","article-title":"Simultaneous quantification of serotonin, dopamine and noradrenaline levels in single frontal cortex dialysates of free-moving rats reveals a complex pattern of reciprocal auto- and heteroreceptor mediated control release","volume":"84","author":"Gobert","year":"1998","journal-title":"Neuroscience"},{"issue":"4","key":"10.1016\/j.pharep.2014.06.009_bib0230","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1016\/S0306-4522(99)00211-0","volume":"93","author":"Gobert","year":"1999","journal-title":"Neuroscience"},{"issue":"4","key":"10.1016\/j.pharep.2014.06.009_bib0235","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1159\/000104877","article-title":"Effect of addition of yohimbine (alpha-2-receptor antagonist) to the antidepressant activity of fluoxetine or venlafaxine in the in the mouse forced swim test","volume":"80","author":"Dhir","year":"2007","journal-title":"Pharmacology"},{"issue":"2","key":"10.1016\/j.pharep.2014.06.009_bib0240","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1111\/j.1471-4159.1993.tb02148.x","article-title":"Endogenous noradrenaline activates alpha 2-adrenoreceptors on serotonergic nerve endings in human and rat neocortex","volume":"61","author":"Feuerstein","year":"1993","journal-title":"J Neurochem"},{"issue":"3","key":"10.1016\/j.pharep.2014.06.009_bib0245","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1007\/BF00167444","article-title":"In vivo electrophysiological evidence for tonic activation by endogenous noradrenaline of alpha 2-adrenoceptors on 5-hydroxytryptamine terminals in the rat hippocampus","volume":"347","author":"Mongeau","year":"1993","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"issue":"4","key":"10.1016\/j.pharep.2014.06.009_bib0250","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/0028-3908(80)90187-2","article-title":"Suppression of firing activity of 5-HT neurons in the dorsal raphe by alpha-adrenoreceptor antagonists","volume":"19","author":"Baraban","year":"1980","journal-title":"Neuropharmacology"},{"issue":"3\u20134","key":"10.1016\/j.pharep.2014.06.009_bib0255","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/0014-2999(84)90618-6","article-title":"Idazoxan (RX 781094) selectively antagonizes alpha 2-adrenoceptors on rat central neurons","volume":"105","author":"Freedman","year":"1984","journal-title":"Eur J Pharmacol"},{"issue":"4","key":"10.1016\/j.pharep.2014.06.009_bib0260","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/S0028-3908(01)00087-9","article-title":"Noradrenergic modulation of serotonin release in rat dorsal and median raphe nuclei via alpha (1) and alpha (2A) adrenoceptors","volume":"41","author":"Hopwood","year":"2001","journal-title":"Neuropharmacology"},{"issue":"1\u20132","key":"10.1016\/j.pharep.2014.06.009_bib0265","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S0006-8993(99)01339-6","article-title":"Histamine regulates food intake through modulating noradrenaline release in the para-ventricular nucleus","volume":"828","author":"Kurose","year":"1999","journal-title":"Brain Res"},{"issue":"Suppl. 1","key":"10.1016\/j.pharep.2014.06.009_bib0270","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1097\/00004714-199704001-00004","article-title":"The clinical relevance of preclinical data: mirtazapine, a model compound","volume":"17","author":"Delbressine","year":"1997","journal-title":"J Clin Psychopharmacol"},{"issue":"2","key":"10.1016\/j.pharep.2014.06.009_bib0275","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1586\/14737175.1.2.171","article-title":"Newer antipsychotics: comparative review of drug interactions","volume":"1","author":"Spina","year":"2001","journal-title":"Exp Rev Neurotherapeutics"},{"issue":"4","key":"10.1016\/j.pharep.2014.06.009_bib0280","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/S1043-6618(03)00178-6","article-title":"Lack of pharmacokinetic interaction between mirtazapine and the newer antipsychotic clozapine, risperidone and olanzapine in patients with chronic schizophrenia","volume":"48","author":"Zoccali","year":"2003","journal-title":"Pharmacol Res"}],"container-title":["Pharmacological Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1734114014002205?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1734114014002205?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T20:35:35Z","timestamp":1752611735000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1016\/j.pharep.2014.06.009"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12]]},"references-count":56,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["S1734114014002205"],"URL":"https:\/\/doi.org\/10.1016\/j.pharep.2014.06.009","relation":{},"ISSN":["1734-1140"],"issn-type":[{"type":"print","value":"1734-1140"}],"subject":[],"published":{"date-parts":[[2014,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The effect of risperidone on the mirtazapine-induced changes in extracellular monoamines in the rat frontal cortex","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharep.2014.06.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Institute of Pharmacology, Polish Academy of Sciences. Published by Elsevier Urban & Partner Sp. z o.o. All rights reserved.","name":"copyright","label":"Copyright"}]}}